Recombinant HRP Anti-DLL3 antibody [EPR22592-18] (ab305810)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- HRP Rabbit monoclonal [EPR22592-18] to DLL3
- Suitable for: Target binding affinity, Antibody labelling
- Conjugation: HRP
Related conjugates and formulations
Overview
-
Product name
HRP Anti-DLL3 antibody [EPR22592-18]
See all DLL3 primary antibodies -
Description
HRP Rabbit monoclonal [EPR22592-18] to DLL3 -
Host species
Rabbit -
Conjugation
HRP -
Tested applications
Suitable for: Target binding affinity, Antibody labellingmore details -
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
General notes
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone. This conjugated antibody is eligible for Abtrial: learn more here.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle. Store In the Dark. -
Storage buffer
pH: 7.40
Preservative: 0.1% Proclin 300 Solution
Constituents: 30% Glycerol (glycerin, glycerine), 1% BSA, 68% PBS -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR22592-18 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
- Anti-DLL3 antibody [EPR22592-18] - BSA and Azide free (ab255694)
- AP Anti-DLL3 antibody [EPR22592-18] (ab308729)
- Alexa Fluor® 488 Anti-DLL3 antibody [EPR22592-18] (ab309688)
- Alexa Fluor® 647 Anti-DLL3 antibody [EPR22592-18] (ab310054)
- Alexa Fluor® 594 Anti-DLL3 antibody [EPR22592-18] (ab310446)
- Alexa Fluor® 555 Anti-DLL3 antibody [EPR22592-18] (ab311973)
- Alexa Fluor® 568 Anti-DLL3 antibody [EPR22592-18] (ab312447)
-
Isotype control
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab305810 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
Target binding affinity |
Use at an assay dependent concentration.
|
|
Antibody labelling |
Use at an assay dependent concentration.
|
Notes |
---|
Target binding affinity
Use at an assay dependent concentration. |
Antibody labelling
Use at an assay dependent concentration. |
Target
-
Function
Inhibits primary neurogenesis. May be required to divert neurons along a specific differentiation pathway. Plays a role in the formation of somite boundaries during segmentation of the paraxial mesoderm. -
Involvement in disease
Spondylocostal dysostosis 1 -
Sequence similarities
Contains 1 DSL domain.
Contains 6 EGF-like domains. -
Domain
The DSL domain is required for binding to the Notch receptor. -
Post-translational
modificationsUbiquitinated by MIB (MIB1 or MIB2), leading to its endocytosis and subsequent degradation. -
Cellular localization
Membrane. - Information by UniProt
-
Alternative names
- Delta Drosophila like 3 antibody
- Delta like 3 Drosophila antibody
- Delta like 3 homolog Drosophila antibody
see all
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
References (0)
ab305810 has not yet been referenced specifically in any publications.